Invited Speakers
Program
Wednesday 3rd May, 2023
08:00-09:00
Registration, Gathering and Exhibition
09:00-11:15
Session 1
Chairpersons: Dr. Ofir Wolach & Dr. Itai Levi
09:00-09:30 - Opening Remarks
09:30-10:05- Non-Ph+ ALL
Hagop Kantarjian, MD, MD Anderson, Houston, USA
10:05-10:40 - Are we ready for risk-adapted therapy in CML
Timothy Hughes, MD, SAHMRI Beat Cancer, University of Adelaide, Australia
10:40-11:15 - Novel prediction models in cancer associated thrombosis
Jeffrey I. Zwicker, MD,Memorial Sloan Kettering Cancer Center, NY, USA
Coffee Break
11:15-11:45
Session 2
11:45-13:30
Chairpersons: Dr. Avi Leader & Dr. Tamar Tadmor
11:45-12:20 - Personalized induction strategies for AML
Gail J. Roboz, MD, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA
12:20-12:55 - Updates in T cell lymphoma with focus on emerging cellular therapies
Swaminathan Padmanabhan Iyer, MD, MD Anderson, Houston, USA
12:55-13:30 - Present and future of molecular testing in CML
Simona Soverini, Ph.D, Alma Mater Studiorum Universita di Bologna, Italy
13:30-14:45
Lunch Break & Guided museum tour
14:45-17:05
Session 3
Chairpersons: Dr. Anat Gafter- Gvili & Dr. Luliana Vaxman
14:45-15:20 - Acute lymphoblastic leukemia at a single base resolution
Gidi Rechavi, MD, Sheba Cancer Research Center, Tel-Hashomer, Israel
15:20-15:55 - Moving towards personalized therapy for Hodgkin lymphoma
Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, NY,USA
15:55-16:30 - When not to transplant in ALL?
Elias Joseph Jabbour, MD, MD Anderson, Houston, USA
16:30-17:05 - Should high risk smoldering myeloma be treated outside of a clinical trial?
Morie Gertz, MD, Mayo Clinic, Rochester Minnesota, USA
17:05-17:15
Closing Remarks
Thursday 4th May, 2023
08:15-09:00
Registration, Gathering and Exhibition
09:15-11:00
Session 4
Chairperson: Dr. Tzila Zuckerman & Dr. Avichai Shimoni
09:00-09:15 - Opening Remarks
09:15-09:50 - HMA/VEN...and then?
Richard Stone, MD, Dana Farber, Boston, USA
09:50-10:25 - Dormancy as a mechanism of innate resistance to therapy in myeloid malignancies Michael Deininger, MD, Versiti, USA
10:25-11:00 - Ph+ ALL today
Robin Foa, MD, "Sapienza" University of Rome, Italy
11:00-11:30
Coffee Break
11:30-13:15
Session 5
Chairpersons: Dr. Merav Leiba & Dr. Nadav Sarid
11:30-12:05 - From broad to ultra targeted therapeutic approaches in CML: which one is best?
Delphine Rea, MD, Hôpital Saint Louis, Paris, France
12:05-12:40 - CML treatment discontinuation in clinical practice: how can we ameliorate its feasibility?
Giuseppe Saglio, MD, University of Turin, Italy
12:40-13:15- Lymphoma/cellular therapy
Loretta Nastoupil, MD, MD Anderson, Houston, USA
13:30-14:45
Lunch Break & Guided museum tour
14:30-17:20
Session 6
Chairpersons: Dr. Moshe Gatt & Dr. Ariel Aviv
14:30-15:05 - Anticoagulant-related bleeding in Cancer
Kristen Sanfilippo, MD, Washington University School of Medicine in St. Louis,USA
15:05-15:40 - T-cell lymphoma
Steve Horwitz, MD, Memorial Sloan Kettering Cancer Center NY, USA
15:40-16:15 - Advances and remaining challenges for patients with Follicular Lymphoma
Gilles Salles, MD, Memorial Sloan Kettering Cancer Center NY, USA
16:15-17:20 - Novel agents in CLL: better sequenced or combined
Jan Burger, MD, MD Anderson, Houston, USA
17:20-17:30
Closing Remarks
Friday 5th May, 2023
09:00-12:00- Round Table Symposiums
09:00-10:00- CLL and Plasma Cell Dyscrasias
Participants:
-
Jan Burger, MD, Houston, USA
-
Morie Gertz, MD, Rochester, USA
-
Tamar Tadmor, MD, Haifa, Israel
-
Iuliana Vaxman, MD, Petah-Tikva, Israel
-
Gilad Itchaki, MD, Petah-Tikva, Israel \
10:00--11:00- Chronic Myeloid Leukemia
Participants:
-
Simona Soverini, Ph.D, Bologna, Italy
-
Giuseppe Saglio, MD, Turin, Italy
-
Pia Raanani, MD, Petah- Tikva, Israel
-
Mr. Giora Sharf, Expert Patient Advocate, Israel
11:00-12:00- Acute Leukemia
Participants:
-
Hagop Kantarjian, MD, Houston, USA
-
Gail Roboz, MD, New York, USA
-
Richard Stone, MD, Boston, USA
-
Robin Foa, MD, Rome, Italy
-
Ofir Wolach, MD, Petah-Tikva, Israel